• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Biomedical Science >Herbal Extract of Gynostemma Pentaphyllum Decreases Hepatic Glucose Output in Type 2 Diabetic Goto-Kakizaki Rats
【24h】

Herbal Extract of Gynostemma Pentaphyllum Decreases Hepatic Glucose Output in Type 2 Diabetic Goto-Kakizaki Rats

机译：绞股蓝的草药提取物可降低2型糖尿病五加崎崎大鼠的肝葡萄糖输出量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of the study was to explore the effect of Gynostemma pentaphyllum (GP) extract on hepatic glucose output (HGO) in spontaneously type 2 diabetic Goto-Kakizaki (GK) rats treated orally with GP or placebo extract 1600 mg/kg daily, during three days or three weeks. The three-week treatment of GP, but not three-day treatment, significantly reduced plasma glucose (PG) levels from 9.8 ± 0.6 to 6.8 ± 0.4 mmol/L (p=0.027) in GK rats, whereas PG levels were not significantly decreased in the placebo rats. Glucose tolerance assessed by an intra-peritoneal glucose tolerance test was significantly improved in GP treated compared to placebo treated group (areas under the glucose curves, AUCs, from 0 to 120 min were 1150 ± 200 vs. 1761 ± 87 mmol/L; p=0.013). The glucose response in an intra-peritoneal pyruvate tolerance test from minute 15 to minute 120, the AUC (15-120) was significantly lower in the GP group (415.5 ± 68.0 vs. 641.5 ± 41.8 mmol/L; p0.05). In liver perfusions, the AUCs for HGO during 18 min (0-18 min) were significantly decreased in GP treated rats compared with control rats (302.8 ± 36.5 vs. 423.5 ± 44.7 µmol, p0.05). The three-week GP treatment significantly reduced the hepatic glycogen content, but not glycogen synthase activity compared to placebo group (p0.007). In conclusion, three-week treatment of GP extract exerted anti-diabetic effect in GK rats, reducing plasma glucose levels and HGO, suggesting that GP improves the hepatic insulin sensitivity by suppressing gluconeogenesis.
机译：该研究的目的是探讨绞股蓝绞股蓝（GP）提取物对口服GP或安慰剂提取物每天口服1600 mg / kg的自发性2型糖尿病Goto-Kakizaki（GK）大鼠的肝葡萄糖输出（HGO）的影响。三天或三周。 GP的三周治疗而非三天的治疗显着降低了GK大鼠的血浆葡萄糖（PG）水平从9.8±0.6降至6.8±0.4 mmol / L（p = 0.027），而PG水平并未显着降低在安慰剂大鼠中。与安慰剂治疗组相比，GP腹腔内葡萄糖耐量测试评估的葡萄糖耐量显着提高（葡萄糖曲线下的面积，AUCs在0至120分钟时分别为1150±200和1761±87 mmol / L; p = 0.013）。在GP组中，腹膜内丙酮酸耐受性试验从第15分钟到第120分钟的葡萄糖反应AUC（15-120）显着降低（415.5±68.0 vs. 641.5±41.8 mmol / L; p <0.05）。在肝灌注中，与对照组相比，GP治疗的大鼠在18分钟（0-18分钟）内HGO的AUCs明显降低（302.8±36.5 vs. 423.5±44.7 µmol，p <0.05）。与安慰剂组相比，为期三周的GP治疗显着降低了肝糖原含量，但未降低糖原合酶活性（p <0.007）。总之，三周的GP提取物治疗对GK大鼠具有抗糖尿病作用，可降低血浆葡萄糖水平和HGO，这表明GP可通过抑制糖异生来改善肝胰岛素敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号